

Protein design algorithms predict viable resistance to an experimental antifolate

Stephanie M. Reeve^{a,1}, Pablo Gainza^{b,1}, Kathleen M. Frey^{a,2}, Ivelin Georgiev^{b,3}, Bruce R. Donald^{b,c,4}, and Amy C. Anderson^{a,4}

^aDepartment of Pharmaceutical Sciences, University of Connecticut, Storrs, CT 06269; and Departments of ^bComputer Science and ^cBiochemistry, Duke University, Durham, NC 27708

Edited by Anne Parle-McDermott, Dublin City University, Dublin, Ireland, and accepted by the Editorial Board December 5, 2014 (received for review June 23, 2014)

Methods to accurately predict potential drug target mutations in response to early-stage leads could drive the design of more resilient first generation drug candidates. In this study, a structure-based protein design algorithm (K* in the OSPREY suite) was used to prospectively identify single-nucleotide polymorphisms that confer resistance to an experimental inhibitor effective against dihydrofolate reductase (DHFR) from *Staphylococcus aureus*. Four of the top-ranked mutations in DHFR were found to be catalytically competent and resistant to the inhibitor. Selection of resistant bacteria in vitro reveals that two of the predicted mutations arise in the background of a compensatory mutation. Using enzyme kinetics, microbiology, and crystal structures of the complexes, we determined the fitness of the mutant enzymes and strains, the structural basis of resistance, and the compensatory relationship of the mutations. To our knowledge, this work illustrates the first application of protein design algorithms to prospectively predict viable resistance mutations that arise in bacteria under antibiotic pressure.

drug resistance | antifolate | protein design | DHFR | MRSA

Effectively treating infectious disease has become increasingly complicated by the prevalence of strains that are resistant to multiple classes of antimicrobial agents. Ideally, the lifetime of newly introduced drugs could be extended by prospectively predicting and overcoming potential resistance during the discovery cycle. For example, mutations to a drug target in response to an experimental candidate could be predicted in silico, and the results could be used to design a second generation of compounds that is active against the WT and mutated enzymes. Minimally, a successful algorithm would predict resistance mutations that maintain enzyme function and reduce inhibitor affinity. However, a more powerful algorithm would also predict mutations that maintain the fitness of the pathogen and are, therefore, likely to be selected in vitro or in vivo. Predicting fit mutations is a significant challenge, because the variables that contribute to fitness in an organism are complex and often unknown. Additionally, a successful algorithm would predict novel mutations that are responsive to novel compounds. A prospective strategy such as this would be especially effective in the discovery of therapeutics for which it is difficult to generate resistant cells in vitro.

In a previous work (1), we used the structure-based K* algorithm in the OSPREY protein design suite (2, 3) to predict double mutations in dihydrofolate reductase (DHFR) from methicillin-resistant *Staphylococcus aureus* (MRSA) that confer resistance to the novel propargyl-linked antifolates. *S. aureus* DHFR (SaDHFR) is an ideal model system for these predictions because the development of a single amino acid mutation results in trimethoprim resistance; higher levels of resistance are conferred by double mutations (4). Although the propargyl-linked antifolates exhibit greater affinity for the mutant enzymes and are active against MRSA strains resistant to trimethoprim-sulfamethoxazole (5), it would be useful to predict mutations that may arise for this new

class of antifolates. Using ratios of positive design scores that predict binding of the substrate dihydrofolate and negative design scores that predict binding of the inhibitor, OSPREY/K* (2, 3) identified catalytically competent resistance mutations.

Additional previous attempts to predict mutational drug resistance have been reported; a recent review summarizes efforts using computational and structural methodologies (6). In contrast to the approach reported here, these other attempts have been retrospective, correlating computational results with approved therapeutics and known mutations in the target (7–10). Because these studies are retrospective analyses of known mutations that arise under pressure from known drugs, they do not address the problem of prospectively predicting a fit mutation.

Herein, we report the application of the structure-based protein design algorithm K* in OSPREY to identify prospective single-nucleotide polymorphisms (SNPs) that confer resistance to one of the propargyl-linked antifolates. For these studies, we required the algorithm to identify an SNP that conferred resistance and would, therefore, be more likely to be selected in the bacteria. From a ranked list of potential SNPs, we created and evaluated four of the mutant enzymes and found that all four conferred resistance (2- to 58-fold) at the enzyme level

Significance

Computationally predicting drug resistance mutations early in the discovery phase would be an important breakthrough in drug development. The most meaningful predictions of target mutations will show reduced affinity for the drug while maintaining viability in the complex context of a cell. Here, the protein design algorithm K* in Osprey was used to predict a single-nucleotide polymorphism in the target dihydrofolate reductase that confers resistance to an experimental antifolate in the preclinical discovery phase. Excitingly, the mutation was also selected in bacteria under antifolate pressure, confirming the prediction of a viable molecular response to external stress.

Author contributions: S.M.R., P.G., K.M.F., I.G., B.R.D., and A.C.A. designed research; S.M.R., P.G., K.M.F., and I.G. performed research; S.M.R., P.G., K.M.F., I.G., B.R.D., and A.C.A. analyzed data; and S.M.R., P.G., B.R.D., and A.C.A. wrote the paper.

The authors declare no conflict of interest.

This article is a PNAS Direct Submission. A.P.-M. is a guest editor invited by the Editorial Board.

Data deposition: The crystallography, atomic coordinates, and structure factors have been deposited in the Protein Data Bank, www.pdb.org (PDB ID codes 4Q6A and 4Q67).

¹S.M.R. and P.G. contributed equally to this work.

²Present address: Department of Pharmacology, Yale University School of Medicine, New Haven, CT 06520.

³Present address: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

⁴To whom correspondence may be addressed. Email: amy.anderson@uconn.edu or brd+dhfr14@cs.duke.edu.

This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10.1073/pnas.1411548112/-DCSupplemental.

Table 2. Characterization of strain susceptibility and fitness

Strain	MIC compound 1 ($\mu\text{g/mL}$; fold loss)	MIC TMP ($\mu\text{g/mL}$; fold loss)	Relative fitness	Doubling time (min)
WT	0.0781	0.3123	1	22.5
F98Y	2.5 (32)	10 (32)	0.98	23.2
V31L/F98Y	20 (256)	40 (128)	0.86	25.4

minimal (14%) loss of fitness. Log-phase cell growth was minimally affected by the presence of the single F98Y or double V31L/F98Y mutation, with doubling times at 22.5 min for the WT strain and 23.2 and 25.4 min for the mutants, respectively.

To understand why the V31L mutation arises only in the background of the F98Y mutation, we examined detailed inhibition and kinetic data for the enzymes. Here, we also included the F98Y mutation and data for trimethoprim as a comparator. The Sa(F98Y) mutation affects trimethoprim more significantly, resulting in 38- and 5-fold losses in K_i against trimethoprim and compound **1**, respectively. However, the Sa(V31L) mutation affects compound **1** more significantly, resulting in 15- and 60-fold losses in K_i against trimethoprim and compound **1** (Table 3). The Sa(V31L/F98Y) double mutant clearly confers much greater resistance, with a 148-fold loss in K_i for trimethoprim and an 189-fold loss in K_i for compound **1**.

Michaelis–Menten constants were determined for the enzymes (Table 3), revealing an interesting compensatory relationship between the mutations. The K_m value for DHF is reduced from the WT value (17.5 μM) by 2-fold for Sa(F98Y)DHFR to 8.4 μM , whereas the same value for Sa(V31L)DHFR is increased by 2.4-fold to 42.9 μM . In combination, the Sa(V31L/F98Y)DHFR restores the K_m for DHF to 4.1 μM . Interestingly, the K_m value for NADPH for Sa(F98Y) increases to 56.8 μM from the WT value of 32.6 μM , and the K_m value for NADPH in Sa(V31L) decreases to 15.6 μM . The double mutant maintains the decreased K_m of Sa(V31L) and has an overall lower K_m relative to the WT at 22.3 μM . Taken together, the data show that, although F98Y and V31L negatively affect NADPH and DHF, respectively, the two mutations combined restore the K_m values to WT levels. Additionally, the k_{cat}/K_m value for the double mutant is increased to 10.9 μM^{-1} .

Structure of Sa(V31L/F98Y)DHFR

The data in Tables 1 and 3 indicate that the mutations have a direct influence on substrate and cofactor binding as well as inhibitor potency. To understand the structural effects of the mutations, we determined a crystal structure of the double-mutant enzyme. Crystals of Sa(V31L/F98Y)DHFR produced diffraction amplitudes to 2.1 Å when cocrystallized with NADPH and a propargyl-linked antifolate (statistics for data and refinement are found in Table 4, and electron density is shown in Fig. S3). The structure was solved using Fourier methods based on the model of single-mutant Sa(F98Y) bound to NADPH and a propargyl-linked antifolate [Protein Data Bank (PDB) ID code 3F0U] (13). The Sa(V31L/F98Y) structure features the standard extended form of NADPH but lacks compound **1** present during cocrystallization.

Comparisons of the Sa(V31L/F98Y) structure with the structure of the WT enzyme bound to compound **1** (Fig. 24) reveal a structural basis of resistance indicated by significant conformational changes induced by the presence of the two mutations. A full table of interactions of the amino acids and compound **1** is presented in Dataset S1. The most significant amino acid reorientations are observed between Phe-92, Val-3, and the binding site of the diaminopyrimidine moiety of compound **1**. The major change centers on Leu-31, which projects 2.0 Å farther into the active site than the WT Val-31 residue, resulting in a corresponding 2.3-Å shift in Phe-92 into the active site and a 1.4-Å shift of the backbone carbonyl (Fig. 24). This new Phe-92 orientation restricts the side chain from adopting the position needed for ligand binding and disrupts stabilizing hydrophobic interactions with the acetylene linker. The shift of the Phe-92 carbonyl also results in the loss of a hydrogen bond to the four-amino group of the pyrimidine. Additionally, Leu-31 is 2.2 Å from the 6-ethyl substituent of the diaminopyrimidine, resulting in repulsive steric interactions.

Furthermore, the B helix adjacent to the active site and possessing critical amino acids for ligand binding shifts 0.4 Å away from the active site. Distances between the ligand and amino acids Asn-25, Asp-27, His-30, and Leu-34 are increased by 0.4 Å, concomitantly reducing hydrogen bonding and van der Waals interactions essential for stability and ligand binding. Moreover, the shift in the B helix results in a 1.1-Å shift in the imidazole ring of His-30. The shifted His-30 side chain extends the binding site, allowing for a glycerol molecule to displace a water molecule that typically provides stabilizing hydrogen bonds between the pyrimidine amino group of **1** and the His-30 imidazole (Fig. S4). A similar disruption of the water network has been previously shown in a crystal structure of the clinically observed resistance mutant Sa(H30N/F98Y) with NADPH and a propargyl-linked antifolate (14). Combined, the observations for Phe-92, Leu-31, and the B helix explain the lower affinity of compound **1** for the mutant enzyme.

The Sa(V31L/F98Y) enzyme maintains catalytic competency. Comparisons of the Sa(V31L/F98Y) structure with WT Sa/NADPH/DHF (PDB ID code 3FRD) (15) indicate that a shift in the Phe-92 peptide carbonyl would have little or no effect on DHF binding or turnover, because there are no direct interactions between the two groups. Any minor steric interactions between Phe-92 and the pterin ring of DHF may be compensated by the additional interactions in the glutamate tail, which remains undisturbed.

To verify which structural effects result from the presence of the mutations and which result from an enzyme lacking a bound ligand, we determined the structure of Sa(F98Y)DHFR bound only to NADPH (statistics for data and refinement are found in Table 4). Comparisons of the structures of binary Sa(F98Y):NADPH, Sa(F98Y/V31L):NADPH, and ternary Sa:NADPH:**1** indicate that the reorientations of Phe-92 and His-30 are caused by the presence of the mutations. Like the Sa(F98Y/V31L):NADPH structure, the Sa(F98Y):NADPH structure features the same 0.4-Å shift of the B helix away from the active site. However, the conformation of Phe-92 in the Sa(F98Y/V31L) structure is clearly influenced by the V31L mutation, because the conformation of this residue in the Sa(F98Y) structure is ~ 0.5 Å

Table 3. Enzyme characterization

DHFR	K_i (TMP; fold loss; μM)	K_i (compound 1 ; μM)	K_m (DHF; μM)	K_m (NADPH; μM)	k_{cat}	k_{cat}/K_m
WT	0.0035 ± 0.0005	0.0028 ± 0.0002	17.5 ± 2	32.6 ± 4	106.9 ± 2	6.1 ± 0.3
F98Y	0.131 ± 0.004 (38)	0.013 ± 0.001 (5)	8.4 ± 0.7	56.8 ± 5	44.7 ± 0.4	5.33 ± 0.08
V31L	0.054 ± 0.002 (15)	0.17 ± 0.02 (60)	42.9 ± 3	15.6 ± 3	68.8 ± 2	1.60 ± 0.06
V31L/F98Y	0.52 ± 0.03 (148)	0.53 ± 0.03 (189)	4.1 ± 0.8	22.3 ± 2	44.8 ± 2	10.9 ± 0.8

Table 4. Crystallographic data collection and refinement statistics

	Sa(V31L/F98Y):NADPH	Sa(F98Y):NADPH
PDB ID code	4Q6A	4Q67
Space group	P6 ₁ 22	P6 ₁ 22
No. monomers in asymmetric unit	1	1
Unit cell (<i>a</i> , <i>b</i> , <i>c</i> ; Å)	79.33, 79.33, 107.53	79.26, 79.26, 107.42
Resolution (Å)	50.00–2.10 (2.14–2.10)	42.30–2.04 (2.51–2.04)
Completeness % (last shell; %)	99.87 (100)	98.7 (98.5)
Unique reflections	12,235	13,132
Redundancy (last shell)	13.7 (13.5)	10.22 (10.44)
<i>R</i> _{sym} (last shell)	0.094 (0.320)	0.070 (0.340)
< <i>I</i> /σ> (last shell)	31.7 (20.0)	16.9 (5.6)
<i>R</i> _{factor} / <i>R</i> _{free}	0.1647/0.2063	0.1752/0.2330
No. of atoms (protein, ligands, and solvent)	1,510	1,446
rmsd Bond lengths (Å), angles (°)	0.008, 1.214	0.007, 1.205
Average B factor for protein (Å ²)	19.57	28.75
Average B factor for ligand (NADPH; Å ²)	14.32	21.11
Average B factor for solvent molecules (Å ²)	32.75	35.18
Residues in most favored regions (%) [*]	98.14	98.10
Residues in additional allowed regions (%) [*]	1.86	1.90
Residues in disallowed regions (%) [*]	0	0
Collection location	BNL X4A	Rigaku Micromax-007 HF

^{*}Ramachandran plot analysis.

closer to that observed in the ternary structure. Similarly, the V31L mutation influences the conformation of His-30, because a comparison of the Sa(F98Y):NADPH and ternary (Sa: NADPH:1) structures shows that the His-30 conformation is the same (Fig. 2B).

Comparisons of the crystal structure of Sa(F98Y/V31L): NADPH (Fig. 2A) with the lowest energy-predicted structure of the K^{*}-predicted single V31L mutant (Fig. 1) show a conservation of the effect of the V31L mutation on Phe-92. The predicted structure also indicates a steric interaction between Leu-31 and the C-6-ethyl substituent of the pyrimidine ring of compound 1, which matches the crystallographic results. Incidentally, when K^{*} was used to predict resistance mutations with another propargyl-linked antifolate that maintains the same atoms as compound 1 other than possessing a methyl instead of an ethyl group at the C-6 position of the pyrimidine ring, the Val-31 mutants ranked lower than the Leu-5 mutations. These results validate that the steric interaction between Leu-31 and the ethyl group specifically contributes to resistance.

In summary, the K^{*} algorithm in OSPREY was used to predict unique single mutations in the active site of *S. aureus* DHFR that confer resistance to an experimental propargyl-linked antifolate, 1. Four of the predicted mutant enzymes were created and shown to be catalytically competent and resistant to compound 1, with the top-ranked mutant having a 58-fold reduction in inhibitor potency. Excitingly, the computational predictions were shown to be not only biochemically validated but also, selected in the bacteria under antibiotic pressure, because the top-ranked mutation, V31L, was selected in the background of an F98Y mutation, which has been clinically observed. Exploration of the enzymatic fitness of this double mutant revealed a compensatory relationship between the single F98Y and V31L mutations that results in a doubly mutated enzyme with fitness comparable with the WT enzyme. Consideration of the cellular fitness revealed that the double-mutant strain only suffered a slight loss in fitness over both the progenitor strain and the previously characterized F98Y strain. Crystal structures




Fig. 2. Crystal structures of the WT and mutant enzymes show conformational changes at Phe-92 and His-30. (A) Superposition of the structures of Sa(WT): NADPH:1 from PDB ID code 3SGY (blue) with Sa(V31L/F98Y):NADPH (magenta). (B) Superposition of the structures of Sa(WT):NADPH:1 from PDB ID code 3SGY (blue) with Sa(F98Y):NADPH (yellow) and Sa(V31L/F98Y):NADPH (magenta).

of the double-mutant enzyme revealed the structural basis of compound resistance.

The mutation V31L emerged as the top-ranked SNP that maintained dihydrofolate binding while conferring inhibitor resistance by perturbing Phe-92 and sterically interfering with the C-6-ethyl group of the pyrimidine ring. Interestingly, there is a strong correlation between these results and those obtained in the first application of K^* to identify double mutants of SaDHFR that confer resistance. In a previous study (1), the seven top-ranked mutations were variants of Val-31 and Phe-92; a crystal structure of the V31Y/F92I mutant enzyme shows that the F92I mutation reduces van der Waals interactions and that the V31Y mutation introduces destabilizing steric bulk. Overall, it is striking that the same structural effect is selected with both applications of K^* whether it is applied to identify double or SNP mutations.

S1 DHFR (from *dhfrA*), a plasmid-acquired enzyme on transposon Tn4003 that confers high levels (>100-fold) of trimethoprim resistance, shares three of four active-site mutations (F98Y, V31L, G43A, and L51) with the predicted K^* mutations (16). Similar to our conclusions, S1 DHFR crystal structures indicate that F98Y disrupts NADPH binding. In fact, crystal structures with S1 DHFR bound to NADPH and trimethoprim completely lack NADPH in three of six molecules in the asymmetric unit (17); related experiments show that the synergy between NADPH and trimethoprim is eliminated in *dhfrA*. The F98Y mutation has also been shown to disrupt NADPH binding in the context of the propargyl-linked antifolates. When Sa(F98Y) is crystallized with inhibitor, the structure possesses two conformations of NADPH: the standard extended β -NADPH and one with the pyrophosphate moiety in a rotated position (13).

Having validated the mutational prediction capabilities of K^* /OSPReY through bacterial selection of the predicted mutants, the algorithm could potentially be applied to many different research areas. Specifically, the computational prediction of drug resistance mutations could be valuable in cases where it is more difficult to raise mutant strains or cell lines in vitro, such as with viruses or cancer cell lines. Overall, the extension of the computational prediction of drug resistance to observations of biologically relevant mutants provides new opportunities in drug discovery, especially for those targets that are most affected by mutational resistance.

Materials and Methods

Computational Prediction of Resistance Mutations. The K^* algorithm (18, 19) within the OSPReY protein design program (2) predicted binding affinities of DHFR mutants to both DHF (positive design) and compound 1 (negative design). Drug resistance was predicted by ranking each mutant and the WT protein by the K^* ratio: the K^* -positive design score divided by the K^* -negative design score.

The set of mutant sequences was selected by choosing all single-nucleotide mutants of the active-site residues. Nine residues in the active site were modeled as flexible and allowed to mutate by up to one nucleotide (substitution): L5{L/V/I/R/Q}, V6{V/A/L/I/F/D/G}, L20{L/V/I/F/S}, L28{L/V/M/W/F/S}, V31{V/A/I/F/L/D/G}, T46{T/A/R/I/K/S}, I50{I/V/L/M/F/N/S/T}, L54{L/R/Q/V}, and F92{F/V/L/I/Y/S/C}. This combination resulted in a total of 47 sequences. Two structures were used as input: a model of the DHF:DHFR:NADPH WT complex (for the positive design) and a model of compound 1. Because a structure of compound 1 bound to DHFR was not available at the time of the design predictions, compound 1 was modeled on the bound structure of a related DHFR inhibitor [PDB ID code 3FQC (13)]. The mutable residues were allowed to assume any conformation in the continuous conformation space (20) within 9° of the rotamers in the Richardson's penultimate rotamer library (21); in addition, the WT rotamer of Phe-92 was added to the rotamer library. Because of observed conformations of the escape mutations to antifolate inhibitors described in ref. 11, we modeled ~10,000 possible binding conformations of compound 1 to DHFR. These binding poses were first filtered by OSPReY's MinDEE/A* algorithms (18) that searched for the lowest energy conformation of any of the mutants to each of the binding conformations. Conformations with predicted energies above a steric threshold were then pruned, resulting in 1,660 binding

poses for compound 1. We then used the K^* algorithm in OSPReY, a statistical mechanics-derived algorithm that uses the MinDEE/A* algorithms to compute Boltzmann-weighted partition functions over energy-minimized conformational ensembles and generates an approximation to K_a , the association binding constant for a given protein-substrate complex. The resulting K^* scores of mutations for both DHF (positive design) and compound 1 (negative design) were used to compute a ratio of scores between positive and negative designs (Table S1).

Selection of Resistant Bacterial Colonies. Resistant strains were selected by plating overnight culture ($\sim 10^{12}$ cfu/mL) of the progenitor strain, ATCC 43300, or *S. aureus* (F98Y) on Isosensitest Agar (Oxoid) containing compound 1 at six times the MIC of the progenitor strain. After 16–18 h of growth at 37 °C, surviving colonies were harvested for characterization. Genotypic characterization was achieved using direct colony PCR to amplify the *dhfrB* gene using sense primer (5'-ATGACCTTATCCATTCTAGTGC-3'), antisense primer (5'-TTATTTTTTACGAATTAATGTAG-3'), and high-fidelity Taq Polymerase (Takara) (22). Mutation frequencies were calculated based on sequencing results for resistant colonies.

Evaluation of Antibacterial Activity. MICs were determined according to the Clinical and Laboratory Standards Institute Guideline's Standard Microdilution broth assay using a final inoculum of 5×10^5 cfu/mL in Isosensitest Broth (Oxoid) (23). The MIC was defined as the lowest concentration of inhibitor to visually inhibit growth. Growth was monitored at A_{600} after 18 h of incubation at 37 °C. MICs were colorimetrically confirmed using Presto Blue (Life Technologies).

Strain Fitness Determination. Relative strain fitness was determined by pairwise competition assays (24) with trimethoprim as the selective agent. Cell growth was monitored every 20 min by A_{600} , and the doubling time of the strains was determined by monitoring cell growth in the log phase at an absorbance of 600 nm every 15 min for a total of 180 min. Fitness was calculated using the following equation: $\text{Fitness} = \ln(R(24)/R(0))/\ln(S(24)/S(0))$.

Enzyme Expression and Purification. Procedures for cloning the Sa(F98Y)DHFR construct in pET41-a(+) have been previously reported (13). A QuikChange Site-Directed Mutagenesis Kit (Agilent Technologies) was used to mutate Val31 to Leu31 on the Sa(F98Y)DHFR construct using sense (5'-GGCACC-TACCAATGATTGAAACAT-3') and antisense (5'-CCTGTTGATAATTTTAA-AGATGTTTC-3') primers. Mutagenesis was confirmed by sequencing. The recombinant Sa(V31L/F98Y) enzyme was overexpressed in *Escherichia coli* BL21 (DE3; Invitrogen) cells and purified using nickel affinity chromatography (SPrime). Protein was desalted using a PD-10 column (GE Healthcare) into buffer containing 20 mM Tris (pH 7.0), 20% (vol/vol) glycerol, 0.1 mM EDTA, and 2 mM DTT and stored in aliquots at -80 °C.

Enzymatic Inhibition Assays. Enzyme inhibition assays were performed by monitoring the rate of NADPH oxidation by DHFR through absorbance at 340 nm at room temperature in assay buffer containing 20 mM TES (N-[tris(hydroxymethyl)methyl]-2-aminoethanesulfonic acid) (pH 7.0), 50 mM KCl, 0.5 mM EDTA, 10 mM β -mercaptoethanol, and 1 mg/mL BSA using 0.1 mM NADPH and 2 μ M enzyme. Inhibitor, in DMSO, was added to the enzyme-NADPH mixture and allowed to incubate for 5 min before the addition of 0.1 mM DHF in 50 mM TES (pH 7.0).

Enzyme kinetics were determined by nonlinear regression analysis (GraphPad) of data generated by enzyme activity assays using 12.5, 25, 50, 75, and 100 μ M DHF with 20 μ M NADPH to determine the K_m and V_{max} for DHF or 12.5, 25, 50, 75, and 100 μ M NADPH with 50 μ M DHF to determine the K_m and V_{max} for NADPH.

Sa(V31L/F98Y)DHFR and Sa(F98Y) Crystal Structures. Sa(V31L/F98Y)DHFR was cocrystallized with NADPH and a propargyl-linked antifolate using the hanging drop vaporization method. Sa(F98Y)DHFR was cocrystallized with NADPH only. Purified protein (20 mg/mL) was incubated with 2 mM NADPH (Sigma-Aldrich) and 1 mM inhibitor in DMSO [in the case of Sa(V31L/F98Y) DHFR] for 2 h on ice. Equal volumes of the protein-cofactor solution were mixed with an optimized crystallization solution containing 13% PEG 10,000, 0.1 M sodium acetate, 0.1–0.2 M 2-(N-morpholino)ethanesulfonic acid (pH 6.0), and 5% γ -butyrolactone. When stored at 4 °C, conditions typically yielded crystals within 7 d. Crystals were frozen in cryoprotectant buffer containing 25% glycerol. High-resolution data were collected on the X4A Beamline at Brookhaven National Laboratories for Sa(V31L/F98Y)DHFR:

NADPH and the Rigaku HighFlux HomeLab Protein Crystallography X-Ray System at the University of Connecticut for Sa(F98Y):NADPH.

Data for Sa(V31L/F98Y)DHFR:NADPH and Sa(F98Y):NADPH were indexed and scaled using HKL2000 and d*TREK, respectively. Phaser (25) was used to identify molecular replacement solutions for the structures of Sa(V31L/F98Y)DHFR:NADPH and Sa(F98Y):NADPH using PDB ID code 3F0U (13) or 3FQO (13) as probe molecule, respectively. The programs Coot (26) and Phenix (27) were used for structure refinement until acceptable R_{work} and R_{free} were achieved. Structural geometry was evaluated by Procheck (28) and Ramachandran plots.

1. Frey KM, Georgiev I, Donald BR, Anderson AC (2010) Predicting resistance mutations using protein design algorithms. *Proc Natl Acad Sci USA* 107(31):13707–13712.
2. Gainza P, et al. (2013) OSPREY: Protein design with ensembles, flexibility, and provable algorithms. *Methods Enzymol* 523:87–107.
3. Chen CY, Georgiev I, Anderson AC, Donald BR (2009) Computational structure-based redesign of enzyme activity. *Proc Natl Acad Sci USA* 106(10):3764–3769.
4. Dale GE, et al. (1997) A single amino acid substitution in *Staphylococcus aureus* dihydrofolate reductase determines trimethoprim resistance. *J Mol Biol* 266(1):23–30.
5. Viswanathan K, et al. (2012) Toward new therapeutics for skin and soft tissue infections: Propargyl-linked antifolates are potent inhibitors of MRSA and *Streptococcus pyogenes*. *PLoS ONE* 7(2):e29434.
6. Hao G-F, Yang G-F, Zhan C-G (2012) Structure-based methods for predicting target mutation-induced drug resistance and rational drug design to overcome the problem. *Drug Discov Today* 17(19–20):1121–1126.
7. Zhu S, Travis SM, Elcock AH (2013) Accurate calculation of mutational effects on the thermodynamics of inhibitor binding to p38 α MAP kinase: A combined computational and experimental study. *J Chem Theory Comput* 9(7):3151–3164.
8. Ishikita H, Warshel A (2008) Predicting drug-resistant mutations of HIV protease. *Angew Chem Int Ed Engl* 47(4):697–700.
9. Hao G-F, Yang G-F, Zhan C-G (2010) Computational mutation scanning and drug resistance mechanisms of HIV-1 protease inhibitors. *J Phys Chem B* 114(29):9663–9676.
10. Safi M, Lilien RH (2012) Efficient a priori identification of drug resistant mutations using Dead-End Elimination and MM-PBSA. *J Chem Inf Model* 52(6):1529–1541.
11. Frey KM, Viswanathan K, Wright DL, Anderson AC (2012) Prospective screening of novel antibacterial inhibitors of dihydrofolate reductase for mutational resistance. *Antimicrob Agents Chemother* 56(7):3556–3562.
12. Vickers AA, Potter NJ, Fishwick CW, Chopra I, O'Neill AJ (2009) Analysis of mutational resistance to trimethoprim in *Staphylococcus aureus* by genetic and structural modelling techniques. *J Antimicrob Chemother* 63(6):1112–1117.
13. Frey KM, et al. (2009) Crystal structures of wild-type and mutant methicillin-resistant *Staphylococcus aureus* dihydrofolate reductase reveal an alternate conformation of NADPH that may be linked to trimethoprim resistance. *J Mol Biol* 387(5):1298–1308.
14. Frey KM, Lombardo MN, Wright DL, Anderson AC (2010) Towards the understanding of resistance mechanisms in clinically isolated trimethoprim-resistant, methicillin-resistant *Staphylococcus aureus* dihydrofolate reductase. *J Struct Biol* 170(1):93–97.
15. Oefner C, et al. (2009) Increased hydrophobic interactions of iclaprim with *Staphylococcus aureus* dihydrofolate reductase are responsible for the increase in affinity and antibacterial activity. *J Antimicrob Chemother* 63(4):687–698.
16. Dale GE, et al. (1995) Characterization of the gene for the chromosomal dihydrofolate reductase (DHFR) of *Staphylococcus epidermidis* ATCC 14990: The origin of the trimethoprim-resistant S1 DHFR from *Staphylococcus aureus*? *J Bacteriol* 177(11):2965–2970.
17. Heaslet H, et al. (2009) Structural comparison of chromosomal and exogenous dihydrofolate reductase from *Staphylococcus aureus* in complex with the potent inhibitor trimethoprim. *Proteins* 76(3):706–717.
18. Georgiev I, Lilien RH, Donald BR (2008) The minimized dead-end elimination criterion and its application to protein redesign in a hybrid scoring and search algorithm for computing partition functions over molecular ensembles. *J Comput Chem* 29(10):1527–1542.
19. Lilien RH, Stevens BW, Anderson AC, Donald BR (2005) A novel ensemble-based scoring and search algorithm for protein redesign and its application to modify the substrate specificity of the gramicidin synthetase a phenylalanine adenylation enzyme. *J Comput Biol* 12(6):740–761.
20. Gainza P, Roberts KE, Donald BR (2012) Protein design using continuous rotamers. *PLOS Comput Biol* 8(1):e1002335.
21. Lovell SC, Word JM, Richardson JS, Richardson DC (2000) The penultimate rotamer library. *Proteins* 40(3):389–408.
22. Lorian V (2005) *Antibiotics in Laboratory Medicine* (Lippincott Williams & Wilkins, Philadelphia).
23. Clinical Laboratory Standards Institute (2012) *Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement* (Clinical Laboratory Standards Institute, Wayne, PA).
24. Lenski R (1988) Experimental studies of pleiotropy and epistasis in *Escherichia coli*. I. Variation in competitive fitness among mutants resistant to virus T4. *Evolution* 42(3):425–432.
25. McCoy AJ (2007) Solving structures of protein complexes by molecular replacement with Phaser. *Acta Crystallogr D Biol Crystallogr* 63(Pt 1):32–41.
26. Emsley P, Cowtan K (2004) Coot: Model-building tools for molecular graphics. *Acta Crystallogr D Biol Crystallogr* 60(Pt 12 Pt 1):2126–2132.
27. Adams PD, et al. (2010) PHENIX: A comprehensive Python-based system for macromolecular structure solution. *Acta Crystallogr D Biol Crystallogr* 66(Pt 2):213–221.
28. Laskowski R, MacArthur M, Moss D, Thornton J (1993) PROCHECK: A program to check the stereochemical quality of protein structures. *J Appl Crystallogr* 26:283–291.

Inhibitors. The synthesis and characterization of compound **1** have been described (5). Trimethoprim is commercially available (Sigma-Aldrich).

ACKNOWLEDGMENTS. We thank Dennis Wright for providing compound **1** and William Clemons, Kyle Roberts, and all members of the laboratories of B.R.D. and A.C.A. for helpful discussions. The authors gratefully acknowledge the support of National Institutes of Health (NIH) Grants GM 78031 (to B.R.D.) and AI111957 (to A.C.A.). Data for this study were measured at Beamline X4A of the National Synchrotron Light Source.

Supporting Information

Reeve et al. 10.1073/pnas.1411548112




Fig. S1. Computationally predicted effect of the V31L mutation on inhibitor binding. (A) Conformations of WT residues F92 (blue), V31 (orange), and compound 1 (gray) in the bound *Staphylococcus aureus* DHFR–inhibitor complex. Oxygen atoms are red; nitrogen atoms are cyan. (B) Osprey K*-predicted structure for residue F92 (blue), compound 1 (gray), and the mutation V31L showing the computationally predicted model of the V31L mutant. Important steric clashes between the inhibitor and DHFR that occur in the model after the introduction of the V31L mutation are shown as red probe dots (1) drawn with the Protein Interaction Viewer (2). (C) Displacement modeled by Osprey K* of compound 1 and Phe-92 after the introduction of mutation V31L. The model of the V31L mutation is shown in the same colors as in B, whereas the structure of the WT is shown in fine white lines. (D and E) Protonated models of the structures shown in A and B. Cpd, compound.

1. Davis IW, et al. (2007) MolProbity: All-atom contacts and structure validation for proteins and nucleic acids. *Nucleic Acids Res* 35(web server issue):W375–W383.
2. Roberts K, Donald B (2014) *Protein Interaction Viewer*. Available at www.cs.duke.edu/donaldlab/software/proteinInteractionViewer/. Accessed October 25, 2014.




Fig. S2. Sequence chromatographs from the bacterial mutants. A shows the region of the chromatograph surrounding the mutation V31L (GTT → CTT), and B shows the region of the chromatograph surrounding the mutation F98Y (TTT → TAT). This chromatograph is representative of chromatographs from five colonies sequenced showing the V31L/F98Y mutations.

2 of 3

K* rank	Single-nucleotide mutation	Substrate positive design K* score	Negative design compound 1 K* score	Ratio of positive design to negative design
1	V31L	2.16E + 41	3.04E + 19	7.11E + 21
2	V31I	4.87E + 36	8.18E + 14	5.95E + 21
3	L5I	6.06E + 39	3.54E + 24	1.71E + 15
4	L5V	4.01E + 44	3.44E + 30	1.16E + 14
5	L54R	6.31E + 43	1.60E + 30	3.94E + 13
6	L20F	6.06E + 20	1.75E + 07	3.46E + 13
7	V31D	1.54E + 41	5.65E + 32	2.72E + 08
8	L5Q	2.84E + 44	1.20E + 36	2.36E + 08
9	V31A	7.32E + 40	7.86E + 33	9.31E + 06
10	V6G	3.92E + 42	4.27E + 35	9.18E + 06
11	I50L	5.18E + 38	5.69E + 31	9.10E + 06
12	F92S	2.09E + 43	2.52E + 36	8.32E + 06
13	L54Q	2.62E + 42	3.21E + 35	8.14E + 06
14	V31G	2.64E + 40	3.38E + 33	7.80E + 06
15	T46A	2.88E + 42	5.27E + 35	5.46E + 06
16	V6I	1.10E + 43	4.01E + 36	2.75E + 06
17	L28M	3.27E + 42	1.58E + 36	2.07E + 06
18	WT	7.16E + 42	3.66E + 36	1.96E + 06
19	T46S	4.93E + 42	3.46E + 36	1.42E + 06
20	L28F	2.25E + 42	1.73E + 36	1.30E + 06
21	L28W	1.29E + 43	1.01E + 37	1.28E + 06
22	L20S	3.57E + 41	2.95E + 35	1.21E + 06
23	L20I	3.04E + 42	2.94E + 35	1.03E + 06
24	L20V	7.43E + 41	7.40E + 35	1.01E + 06
25	V6A	4.71E + 42	6.07E + 36	7.76E + 05
26	L54V	1.46E + 41	2.68E + 35	5.44E + 05
27	L28S	1.34E + 41	3.74E + 35	3.59E + 05
28	V6D	1.18E + 43	6.05E + 37	1.95E + 05
29	V6L	7.26E + 42	6.47E + 37	1.12E + 05
30	F92V	8.18E + 40	2.80E + 36	2.29E + 04
31	I50V	2.49E + 42	1.74E + 38	1.43E + 04
32	L28V	3.19E + 39	2.37E + 35	1.35E + 04
33	F92I	8.91E + 40	8.48E + 36	1.05E + 04
34	F92C	1.02E + 40	5.37E + 36	1.90E + 03
35	I50S	3.07E + 41	2.37E + 38	1.30E + 03
36	I50T	1.11E + 42	9.85E + 38	1.13E + 03
37	I50N	6.81E + 41	1.53E + 39	4.46E + 02
38	I50M	1.00E + 40	7.50E + 37	1.33E + 02
39	F92L	4.02E + 37	4.20E + 36	9.59E + 00
40	L5R	4.21E + 34	4.27E + 35	9.88E - 02
41	T46I	5.05E + 36	2.25E + 42	2.25E - 06
42	V6F	0.00E + 00	2.94E + 36	0.00E + 00
43	V31F	0.00E + 00	8.69E - 11	0.00E + 00
44	T46R	0.00E + 00	0.00E + 00	0.00E + 00
45	T56K	0.00E + 00	1.14E + 14	0.00E + 00
46	F92Y	0.00E + 00	3.10E + 32	0.00E + 00
47	I50F	0.00E + 00	3.37E + 35	0.00E + 00

Row 18, showing the scores for the wild-type enzyme, is shown in bold for reference.

Dataset S1. Interactions between residues and ligands are shown with notations for distance and van der Waals (V) or hydrogen bond (H)

Dataset S1